Clay Siegall’s Journey with Targeted Cancer Therapies

Dr. Clay Siegall is the founder and Chief Executive Officer of Seattle Genetics which is a biotech firm in Seattle. The firm develops targeted therapy drugs for disorders that have not yet experienced a considerable mortality improvements for a long time. Dr. Clay Siegall has led the firm since its establishment in year 1998 to greater heights and have managed to develop the first FDA-approved antibody drug conjugate and a strong pipeline of over 20 drugs. The firm has also been able to develop strong and strategic relationships with drug manufacturers such as Genentech, Bayer and Pfizer among others.

During an interview with inspirery, Siegall says that the idea of him creating Seattle Genetics came from his deep interest in medicine, technology advancement and his great urge to overcome diseases. He added that his first field of interest was more related to cancer treatment because he had realized that there are other ways of treating cancer apart from chemotherapy and thus wanted to find out more about these methods. Siegall says that one of the ways he earns money from the firm include selling own developed proprietary drugs such as ADCetris. They also earn some revenues from partnering with other drug manufacturers and licensing processes and technologies that they have developed in the firm. The firm battled with some financial threats in year 1999 and 2000 but eventually with great determination they were able to pull through it.

Dr. Siegall told inspirery that they have a dynamite sales team and they all have a rich background in biotech. They also know all the products that the firm deals with and this knowledge helps the close great deals on behalf of the firm.

About Clay Siegall

Dr. Siegall is a co-founder of Seattle Genetics and has been serving the company as the president and CEO since year 2008. Through his leadership, the firm has managed to develop a broad pipeline of antibody drug conjugate such as ADCETRIS which received approval from FDA in year 2011. Dr. Siegall had also worked with Bristol-Myers Squibb Pharmaceutical Research Institute and National Institutes of Health. He is a member of Alder BioPharmaceuticals’ board of directors, an author of over 70 publications and holds about 15 patents. Dr. Siegall graduated from George Washington University with a Ph.D. in Genetics and from University of Maryland with B.S. in Zoology.


One thought on “Clay Siegall’s Journey with Targeted Cancer Therapies”

  1. The facts in industry is one that has witness enormous changes in recent times and the works of Kate, Adam and the rest of them has made that possible. In specifics offers the best of tips about some of the ideas that research and development has brought that is making things work for him in the industry and I think other persons might also be interested in knowing what he is doing right.

Comments are closed.